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Abstract
Background: Compared to very low gestational age (<32 weeks, VLGA) cohorts, very low birth weight (<1500 g;
VLBW) cohorts are more prone to selection bias toward small-for-gestational age (SGA) infants, which may impact
upon the validity of data for benchmarking purposes.
Method: Data from all VLGA or VLBW infants admitted in the 3 Networks between 2008 and 2011 were used.
Two-thirds of each network cohort was randomly selected to develop prediction models for mortality and composite
adverse outcome (CAO: mortality or cerebral injuries, chronic lung disease, severe retinopathy or necrotizing enterocolitis)
and the remaining for internal validation. Areas under the ROC curves (AUC) of the models were compared.
Results: VLBW cohort (24,335 infants) had twice more SGA infants (20.4% vs. 9.3%) than the VLGA cohort (29,180 infants)
and had a higher rate of CAO (36.5% vs. 32.6%). The two models had equal prediction power for mortality and CAO
(AUC 0.83), and similarly for all other cross-cohort validations (AUC 0.81–0.85). Neither model performed well for the
extremes of birth weight for gestation (<1500 g and ≥32 weeks, AUC 0.50–0.65; ≥1500 g and <32 weeks, AUC 0.60–0.62).
Conclusion: There was no difference in prediction power for adverse outcome between cohorting VLGA or VLBW
despite substantial bias in SGA population. Either cohorting practises are suitable for international benchmarking.
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Background
Very premature and very low birth weight (VLBW)
infants are at high risk of mortality and morbidities.
Effective outcome prediction and benchmarking, for par-
ental counseling, quality improvement and informing
the wider community, have their foundation in the out-
come statistics of infant cohorts [1]. There are two
established methods of cohorting high-risk infants, by
birth weight (for example, VLBW, <1500 g) or by gesta-
tional age (for example, very low gestational age [VLGA],
<32 weeks), with the relative advantages of each yet to be
determined. There has been increasing acceptance of
gestational age (GA) based cohorting in recent literature
[2–5], following studies such as that by Arnold et al. in
1991 [6] and Blair et al. in 1996 [6, 7], which raised con-
cerns that VLBW cohorts may be inherently biased.
Birth weight (BW) is dependent on two separate influ-
ences; GA at birth and fetal growth rate [8]. It follows
that a VLBW cohort may contain infants at any point
along a spectrum from very preterm and sized appropri-
ately for their GA (AGA) to small for gestational age
(SGA). There is an inherent selection bias toward SGA
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infants in VLBW cohorts, which becomes more pro-
nounced at higher gestations, as the birth weights of
AGA infants become greater than 1500 g [6, 7, 9]. This
disproportionate SGA percentage is exemplified in pub-
lished studies that have used VLBW cohorts, wherein
19% to 40% of infants were SGA [10–14]. A skewing of
risk toward poorer outcome would be expected even in
multivariate analyses because high-risk SGA infants lack
an equivalent AGA control for adjustment within the
cohort. In comparison, GA is independent of BW and
fetal growth rate [7], and hence fetal growth and BW for
GA show a normal distribution in VLGA cohorts [6].
SGA proportion, by definition, will remain close to 10%
across all published cohorts, where SGA percentage
ranged from 9.2–12% [15, 16].
Meaningful international examination of neonatal
outcomes is currently limited by the variations in
reporting between nations [17], as direct comparison of
neonatal outcomes through benchmarking requires
prior standardization of the infant cohorting method
used for data collection and reporting. The World
Health Organization changed its standard cohorting
practice to GA-based in 1961 [18], but some studies and
analyses persist in the use of BW criteria [1, 19–21].
The overall aim of this study was to evaluate and com-
pare the predictive power of prediction models devel-
oped using VLGA and VLBW-based cohorts. It was
hypothesized that predictive power of the VLGA-based
models would be significantly better than that of the
VLBW-based models across all networks because it
would reduce the selection bias introduced by the
disproportionately high number of SGA infants.
Methods
De-identified clinical data were obtained from the Australian
and New Zealand Neonatal Network (ANZNN), Canadian
Neonatal Network (CNN) and Swedish Neonatal Quality
Register (SNQ) for all infants born either at <32 weeks
gestational age or with birth weights <1500 g, who were
admitted to participating NICUs in between January
2008 and December 2011. Networks were selected
because of their intrinsic similarity, with comparable
demographics and healthcare systems. All three net-
works have the registration criteria for data collection if
admitted infants are either <32 weeks or <1500 g.
Infants were also excluded if they were moribund (died
within the first day of admission without being offered
mechanical ventilation or intensive care) or had major
congenital anomalies.
The parameters for data collection in each of the net-
work databases were compared. Definitions of outcomes
and variables to be analyzed were standardized by con-
sensus a priori. National preterm BW percentiles were
examined for each network, and found to be very similar
in Australia [22] and Canada [23], however in-utero
growth charts were used in the SNQ [24], and therefore
the Swedish percentiles were not comparable. For this
reason, Canadian BW percentile charts were applied to
all infants to define SGA and BW z score.
For the study period, ANZNN data comprised all 29
tertiary hospitals in Australia/New Zealand; CNN com-
prised 28 of 30 tertiary hospitals in Canada; and SNQ all
25 hospitals with neonatal units in 6 of the 7 health care
regions of Sweden. Study data were available through
the iNeo (International Network for Evaluating Out-
comes in Neonates) project housed at Mother-Infant
Care Research Center, Mount Sinai Hospital, University
of Toronto, Canada.
The primary outcome studied was in-hospital mortality.
The secondary outcome was composite adverse outcome
(CAO), defined as in-hospital mortality or a pre-discharge
diagnosis of any major neonatal morbidities of chronic
lung disease (CLD), serious neurological injuries (SNI)
including intraventricular hemorrhage grade III or IV [25]
or periventricular leukomalacia, severe retinopathy of pre-
maturity stage 3 or more (ROP) [26] and radiologically or
pathologically proven necrotizing enterocolitis (NEC) [27],
Consensus outcome definitions are provided in Additional
file 1: Table S1. Nosocomial infection was not included in
CAO but was included in descriptive analyses, as rate of
NI may be used as a marker of patient safety and health-
care effectiveness and outcomes, and hence has relevance
for comparison between international cohorts [28].
Data from all networks were amalgamated and formed
into two overlapping cohorts of infants less than
32 weeks (VLGA) and/or less than 1500 g (VLBW). Ori-
ginating network was added as a covariate for subse-
quent analysis. Of the two overlapping VLBW and
VLGA cohorts, two-thirds (balanced for network) were
randomly selected, using a split sample method [29], to
form the derivation samples for development of two pre-
diction models. The remaining one-third of infants from
each cohort formed the internal validation samples, for
assessment of predictive power on independent samples.
Prediction models were developed for mortality and
CAO by multivariable logistic regression with backwards
procedures using exclusion criteria of 0.05, according to
methodology validated in previous population studies
[30, 31]. The interaction of BW z-score and GA was also
included as a covariate in multivariable analysis to adjust
for the varying confounding effects of growth status and
maturity.
Analysis for prediction power was conducted for each
model on both the VLGA and the VLBW validation
samples, which consisted of the VLBW and VLGA valid-
ation samples, and two mutually exclusive “extreme”
subcomponents of infants <1500 g but ≥32 weeks, and
infants <32 weeks but ≥1500 g. Prediction power was
Koller-Smith et al. BMC Pediatrics  (2017) 17:166 Page 2 of 10
assessed using area under the Receiver Operating Char-
acteristic (ROC) curve [32–34]. An AUC of >0.80 is gen-
erally accepted as excellent prediction [35]. AUC of each
prediction was compared. Goodness-of-fit was
determined by use of the Hosmer-Lemeshow test [13] to
test for systematic over or underestimation of outcomes
by the model [36]. Data management and analyses were
performed using SAS 9.3 [37] and R 2.10.15 [38]. A two-
sided significance level of 0.05 has been used without
adjustment for multiple comparisons.
ANZNN data collection, access and use of de-
identified data for audit and research was approved by
all relevant institutional research ethics committees of
each NICU hospital (see list of hospitals in Acknow-
ledgement) in Australia, and by the New Zealand Multi-
regional Ethics Committee for all the New Zealand
hospitals listed. For the CNN and SNQ, de-identified
data collection was approved at each site by either an
institutional ethics board or quality improvement com-
mittee of the hospitals listed. All participating networks
have obtained ethics/regulatory approval or the equiva-
lent from their local granting agencies to allow for de-i-
dentified data to be collated. De-identified ANZNN,
CNN and SNQ data were amalgamated at the iNeo
collaboration centre where analysis occurred. Approval
for this project was obtained from the South Eastern
Sydney Local Health District Human Research Ethics
Committee and approval for data transfer was obtained
from all three networks executive committees. The ethics
committees waived the requirement for the consent.
Data from all networks were amalgamated and used for
this study.
The Coordinating Centre has been granted Research
Ethics Board approval for the development, compilation,
and hosting of the dataset, and all 3 networks have
signed data transfer agreements with the Coordinating
Centre. Privacy and confidentiality of patient and unit-
related data will be of prime importance to the iNeo
collaboration, and data collection, handling, and trans-
fer will be performed in accordance with the Canadian
Privacy Commissioner’s guidelines, the Personal Infor-
mation Protection and Electronic Documents Act, and
any other local rules and regulations. No data identifi-
able at the patient level will be collected or transmitted,
and only aggregate data will be reported. For all stages
of the project, participating units will be assigned a
code by their own network prior to data transfer into
the iNeo dataset so that units remain anonymous
within the iNeo collaborative. Following data analysis,
findings will be disseminated within networks by their
own network coordination team and not by the iNeo
central team.
Following completion of the study in 2017, the data will
be kept at the iNeo Coordinating Centre for a further 2
years before being returned to the originating networks
unless otherwise agreed by the member networks.
Results
The derivation of the study cohort is detailed in Fig. 1.
The final study population contained 31,940 infants;
14,954 infants from the ANZNN (46.8%), 13,297 (41.6%)
from the CNN and 3689 (11.5%) from the SNQ. The
VLBW cohort was made up of 24,335 infants (76.2% of
study population) and the VLGA cohort of 29,180
infants (91.4% of study population).
The majority of infant characteristics were similar
between the VLGA and VLBW cohorts (see Table 1),
with the expected exception of SGA percentage, which
was more than double in the VLBW cohort (20.4%)
compared to the VLGA cohort (9.3%). For the VLGA
cohort, mean GA was marginally higher for ANZNN
infants (28.5 weeks) than for CNN or SNQ infants
(28.3 weeks). Antenatal steroid use was significantly
lower in the CNN than ANZNN and SNQ. Significantly
fewer infants required exogenous surfactant in the
ANZNN than CNN or SNQ. Similar disparities between
networks were seen in the VLBW cohort.
Neonatal outcomes
In the VLGA cohort (Table 1), mortality rates were simi-
lar across networks while CAO was higher in the CNN
(36.5%) than the ANZNN (28.7%) and SNQ (30.3%).
The same trends were observed in the VLBW cohort.
Mortality rates were similar between the VLBW (8.9%)
and VLGA (7.7%) cohorts. The greatest disparity was in
the higher rates of CLD (21.7% vs. 19.2%) and NI
(18.1% vs. 16.0%) in the VLBW cohort. CAO rate was
higher (36.5% vs. 32.6%) in the VLBW cohort, beyond
the effect of the increased CLD incidence. The neonatal
outcomes of all 3 networks stratified by gestation sub-
groups (22–24, 25–26, 27–28 and 29–31 weeks) and
birth weight (<750 g, 750-999 g, 1000-1249 g and
1250–1499 g) subgroups are summarised in Additional
file 1: Table 2 (a) and (b).
VLGA and VLBW prediction models for mortality and
composite adverse outcome
Mortality prediction models developed using the VLBW
and VLGA derivation cohorts are shown in Table 2.
AUC was analogous for the VLBW (0.830) and VLGA
(0.828) based models, and both models had equally
good discriminatory power. The CAO prediction
models (Table 3) included similar variables to the mor-
tality prediction models. Both the VLGA and VLBW-
based models showed equal discrimination, with an
AUC of 0.83.
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Application of prediction models to validation samples
When applied to the validation samples, the predictive
power of both the VLBW-based and VLGA- based models
remained excellent (AUC 0.81–0.85) for prediction of
mortality and CAO. Cross-comparison showed equivalent
performance between the VLBW and VLGA-based
models for application to both the VLBW and VLGA de-
velopmental samples (Additional file 1: Table 3). Statistical
significance (p < 0.05) was reached between the VLGA
and VLBW-based CAO prediction models for the VLBW
validation sample. Predictive power of the VLBW and
VLGA-based models remained excellent across networks
and exhibited a narrow range in AUC of 0.81 to 0.86. This
demonstrated the applicability of the developed models to
the three included networks. Due to the large sample
sizes, statistical significance was shown between the
VLGA and VLBW models for some comparisons despite
very small differences.
Application of prediction models to extreme subsets
There are two mutually exclusive subset of the cohorts:
2759 infants in the VLBW cohort whose gestation was
32 weeks or above and 7603 infants in the VLGA cohort
whose birthweight was 1500 g or more. Predictive power
decreased when the models were applied to these two
extreme subset of the VLBW and VLGA cohorts (AUC
0.50–0.62) (Table 4). Neither model demonstrated con-
sistently better performance for the prediction of mortal-
ity or CAO in either of the extreme subsets. In the
VLBW and ≥32 week extreme subsets, most (2273/2759,
82.4%) were SGA, and conversely in the extreme VLGA
and ≥1500 g subset a smaller proportion (713/7603,
9.3%) were SGA and a considerable number of infants
(1300/7603, 17.1%) were large for gestation age (LGA).
Both extreme subsets had consistently lower crude mor-
bidity and composite adverse outcome rates than those
of the total cohorts (Additional file 1: Table 4).
Discussion
This study is the first to systematically assess the com-
parative predictive power of VLBW and VLGA cohorting
methods. Belief in the superiority of gestation-based co-
horts has grown amongst many investigators [2, 3, 39–41]
in response to suggestion that VLBW cohorts are limited
by their innate confounding of growth status and maturity
[6–8, 17, 42], but have not been formally validated. In this
Fig. 1 Flow Chart of Study Cohort: derivation of the study infants from each neonatal network is summarised
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Table 1 Comparisons of infant and perinatal characteristics and neonatal outcomes among networks (ANZNN, CNN, SNQ) for very
low gestational age cohort and very low birth weight cohort derived from network admissions 2008–2011
Very low gestational age Very low birth weight
Networks ANZNN CNN SNQ P-value ANZNN CNN SNQ P-value
Total number 13,586 12,167 3427 11,307 10,327 2701
Infant and Perinatal Characteristics
Gestational age, mean(SD) 28.5(2.2) 28.3(2.2) 28.3(2.4) <0.0001 28.3(2.6) 28.2(2.6) 27.9(2.7) <0.0001
Birth weight, mean(SD) 1232 396) 1209 (387) 1234 (424) <0.0001 1082 (274) 1068(267) 1055 (291) <0.0001
Male sex 7345 (54.1) 6617 (54.5) 1838 (53.6) 0.6619 5762 (51.0) 5290(51.3) 1372 (50.8) 0.8571
Small for gestational age 1249 (9.2) 1133 (9.3) 317 (9.3) 0.9515 2369 (21.0) 2082(20.2) 521 (19.3) 0.0999
Singleton 9532 (70.2) 8417 (69.3) 2441 (71.3) 0.0478 7901 (69.9) 7099(68.8) 1930 (71.5) 0.016
Surfactant required 7336 (54.1) 7179 (59.0) 1941 (56.8) <0.0001 6442 (57.1) 6233(60.4) 1649 (61.3) <0.0001
Antenatal steroid use 12,902 (95.1) 10,156 (86.6) 3278 (95.7) <0.0001 10,723 (95.0) 8520(85.7) 2581 (95.6) <0.0001
Caesarean 8478 (62.7) 7117 (59.0) 2086 (61.2) <0.0001 7311 (65.0) 6565(64.1) 1679 (62.7) 0.0613
Presentation (vertex) 8676 (65.4) 7307 (64.7) 2209 (65.7) 0.3872 7099 (64.2) 6004(63.0) 1720 (65.3) 0.0353
Maternal age, mean(SD) 29.8 (6.4) 30.5 (5.9) 29.9 (6.5) <0.0001 29.7 (6.5) 30.5(6.0) 29.8 (6.6) <0.0001
Neonatal Outcomes
Mortality 987 (7.3) 986 (8.1) 265 (7.7) 0.0407 948 (8.4) 945(9.2) 252 (9.3) 0.0841
Severe neurological injury 758 (5.6) 1409 (9.4) 220 (6.4) <0.0001 711 (6.3) 1293(10.1) 202(7.5) <0.0001
Severe retinopathy of prematurity 496 (3.7) 592 (4.9) 146 (4.3) <0.0001 487 (4.3) 596(5.8) 144 (5.3) <0.0001
Necrotising enterocolitis 591 (4.4) 690 (5.7) 143 (4.2) <0.0001 566 (5.0) 641(6.2) 134 (5.0) 0.0002
Chronic lung disease 2381 (17.5) 2597 (21.3) 629 (18.4) <0.0001 2233 (19.8) 2472(23.9) 586 (21.7) <0.0001
Composite adverse outcome 3893 (28.7) 4564 (36.5) 1043 (30.4) <0.0001 3649 (32.3) 4272(40.3) 962 (35.6) <0.0001
Nosocomial Infection 2008 (14.8) 2188 (18.0) 484 (14.1) <0.0001 1869 (16.5) 2069(20.0) 454 (16.8) <0.0001
N (%) are shown unless specified
Notes: the reported p-values were based on chi-square tests for categorical variables, and F tests for continuous variables. Composite adverse outcome is defined
as: death or any major morbidities including chronic lung disease, severe neurological injury, necrotising enterocolitis, severe retinopathy. Nosocomial infection is
not included
Table 2 Predictive models for mortality developed using data from ANZNN, CNN and SNQ 2008–2011
(a) Model based on BW cohort (b) Model based on GA cohort
Covariates Estimate SE P-value Estimate SE P-value
Intercept 14.1797 0.4661 <0.0001 12.9809 0.3814 <0.0001
GA (weeks) −0.6128 0.0182 <0.0001 −0.5629 0.0146 <0.0001
BW z score 1.5657 0.3677 <0.0001 #
GA x BW z score −0.067 0.014 <0.0001 #
Country (Sweden vs CA) # #
Country (Australia vs CA) # #
Gender (male) 0.3499 0.0642 <0.0001 0.2969 0.0616 <.0001
Antenatal steroid use −0.6825 0.104 <0.0001 −0.5745 0.1008 <.0001
Singleton # #
Cesarean # #
Presentation (Vertex) −0.1562 0.0639 0.015 −0.2213 0.0611 0.0003
Area under ROC curve 0.8303 0.0058 0.828 0.00585
Hosmer-Lemeshow test 0.18 0.15
Multiple logistic regression models were applied to obtain the final predictive models using stepwise variable selection procedure with inclusion and exclusion
criterion of 0.05; # = excluded by the variable selection procedure
Notes: BW z score Birth weight z score, GA x BW z score interaction between GA and Birth weight z score, Estimate estimated coefficient of the covariate, SE
standard error
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retrospective population study of 31,940 neonates from
Australia/New Zealand, Canada and Sweden, we identified
that outcome prediction models derived from VLGA and
VLBW cohorts perform equally well for prediction of in-
hospital mortality and CAO in these high-risk preterm
infants.
As expected, the VLBW study cohort held a dispropor-
tionately high number of SGA infants [6–8, 17, 42] in
harmony with previous large population studies, which
show SGA proportions of 20–39% in VLBW groups
[10–13, 43, 44] compared to 8–12% in VLGA groups
[15, 16, 45–47].
The expected skewing of risk toward poor outcome in
VLBW cohorts was confirmed by the higher rate of
CAO in this group (36.5%) compared to the VLGA
group (32.6%). The VLBW study cohort had higher rates
of NI (18.1% vs. 16.0%) and CLD (21.7% vs. 19.2%) than
the VLGA cohort across all networks [48] confirming
previous studies that SGA infants have higher risk of
CLD [49–53] and NI [50, 52, 54] compared to AGA
infants of the same GA. Previous studies have also sug-
gested higher mortality [49–51] and NEC [52] rates in
SGA infants, yet inconclusive as to whether SGA groups
have excess risk of severe ROP and SNI [48, 50, 52, 54].
The current international study has the largest sample
size of any research examining these morbidities and
thus has the statistical power to determine small differ-
ences in outcome. The smaller than hypothesised out-
come difference found between the VLGA and VLBW
groups is likely related to improvement of SGA outcomes
associated with advances in contemporary clinical prac-
tice. The protective effect (negative coefficient) found for
vertex presentation for both VLBW and VLGA cohorts
suggests other presentations such as breech, transverse or
others are associated with a less favourable outcome.
No clinically significant difference in predictive per-
formance was found between the VLGA and VLBW
models in this study. The higher SGA percentage within
the VLBW cohort did not affect the discrimination
power of the VLBW model, suggesting adequate control
within the model for the confounding effect present. We
propose two explanations for the rejection of our
hypothesis. First, in previous VLBW cohort publications,
many infants may not have had accurate prenatal gestation
assessments, primarily due to substantial limitations in ac-
cessibility to early dating ultrasound. In comparison, GA
assessment in the three networks of this contemporary
study was robust, as all three networks have national
healthcare access with nearly universal ultrasound
Table 3 Predictive models for composite adverse outcome developed using data from ANZNN, CNN and SNQ 2008–2011
(a) Model based on BW cohort (b) Model based on GA cohort
Covariates Estimate SE P-value Estimate SE P-value
Intercept 18.66 0.363 <0.0001 17.8 0.285 <0.0001
GA (weeks) −0.682 0.013 <0.0001 −0.649 0.01 <0.0001
BW z score 1.386 0.272 <0.0001 −0.15 0.022 <0.0001
GA x BW z score −0.057 0.01 <0.0001 #
Country (sweden vs CA) −0.427 0.07 <0.0001 −0.326 0.065 <0.0001
Country (Australia vs CA) −0.416 0.045 <0.0001 −0.371 0.042 <0.0001
Gender (male) 0.192 0.042 <0.0001 0.257 0.039 <0.0001
Antenatal steroid use −0.259 0.08 0.0012 −0.237 0.075 0.002
Singleton # #
Cesarean 0.3 0.044 <0.0001 0.241 0.04 <0.0001
Presentation (Vertex) # #
Area under ROC curve 0.837 0.0033 0.835 0.003
Hosmer-Lemeshow test 0.19 0.373
Multiple logistic regression models were applied to obtain the final predictive models using stepwise variable selection procedure with inclusion and exclusion
criterion of 0.05; # = excluded by the variable selection procedure
Notes: BW z score Birth weight z score, GA x BW z score interaction between GA and Birth weight z score, Estimate estimated coefficient of the covariate, SE standard error
Table 4 Cross comparison of predictive power of the very low
birth weight (VLBW) and very low gestational age (VLGA) based
prediction models for application to the total extreme subsets
of the VLGA and VLBW verification cohorts
Extreme subsets BW <1500
& GA ≥32 wk
GA <32
& BW ≥1500
n = 893 n = 2527
Model for mortality based on VLBW cohort 0.605 0.623
Model for mortality based on VLGA cohort 0.504 0.618
Model for CAO based on VLBW cohort 0.649 0.608‡
Model for CAO based on VLGA cohort 0.618 0.622‡
Notes: †: p < 0.01,‡: p < 0.05; Two figures are significantly different if they
share the same symbol. Chi-square test was used for the comparison in
predictive power of the two models
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examinations of pregnancies. The accurate GA data in
both the VLGA and VLBW cohorts improved the accuracy
of the models in this study, compared to expectations from
previously published VLBW cohort data. Second, the
research methodology of this study allowed for inclusion
of non-linear relationships, such as the GA and BW z-
score interaction. In the VLBW models, this adjusted for
growth status and maturity through a balanced shift in the
coefficients for BW z-score and GA as well as the negative
coefficient in their interaction being the protective con-
founding effect of growth status and maturity. The non-
inclusion of these covariates in the VLGA models likely
reflects that similar adjustment for SGA infants was not
needed, as expected in keeping with the consistent 10%
SGA. Consequently, the large sample sizes of this study
combined with sophisticated modelling allowed develop-
ment of models able to effectively control for confounding
and bias, leading to the null findings.
Comparison of the models’ usefulness for prediction in
the two ‘extreme’ subsets of VLGA-not-VLBW and
VLBW-not-VLGA tests the scope of application. It was
found that the power of all models fell when applied to
the <1500 g BW ≥32-week GA infants, who would almost
all be moderately or severely SGA. Predictive power also
dropped for both the VLGA and VLBW models when
used for CAO prediction in the BW ≥1500 g and GA <32-
week subset, but remained excellent for mortality predic-
tion. This clearly confirms that both mortality prediction
models perform well for an extreme cohort containing no
SGA infants [23]. The finding that the CAO prediction
model did not perform as well as expected could indicate
increased vulnerability of large for GA infants to mor-
bidities. The findings suggest that separate prediction
models may need to be developed for infants on the
extreme subsets of established cohorts where there is
a high proportion of SGA or LGA infants, as stand-
ard statistical modelling derived from either VLGA or
VLBW may not be appropriate for use.
This study is reliable due to its large sample size of
31,940, and the population based nature of the data [55].
Relative to the size of the samples there were very few
missing or incorrect data, attesting to the high quality of
the originating databases. The international collaboration
allowed validation of study findings across three neonatal
networks, and was made more effective by choosing net-
works with similar databases. Additionally, Canada, Sweden
and Australia/New Zealand have high coverage with early
dating ultrasound and thus accurate GA data, in contrast
to other studies that have combined last menstrual period
and ultrasound dating, thus applying GA estimations that
differ by up to 3 weeks [8, 56]. Through the examination of
both mortality and CAO, this study will be useful as sur-
vival at lower GA becomes possible and prediction of sur-
vival without major morbidities becomes increasingly vital.
This study was limited to the analysis of variables
collected uniformly across all network databases for the
complete study period, but the similarity and quality of
the network databases included curtailed the effect of
this limitation. The observational, retrospective design
meant that no causal mechanisms can be imputed..
The conclusion that VLBW cohorts perform as well as
VLGA cohorts for prediction of mortality and morbidity
will have ramifications at the international and popula-
tion levels. Comparison of population outcome may now
be considered valid regardless of the cohorting method
used to obtain data, providing both GA and BW z scores
are included in analytic models. This represents a major
advancement in international benchmarking. This study
also provides evidence to justify the continued use of
BW-based cohorting in some nations provided accurate
GA data are included. A further corollary of this study is
clarification of the literature on VLGA and VLBW neo-
nates. The findings elucidate both the external validity of
research based on one cohort for application to the other,
and the appropriateness of comparing data or conclusions
based on disparately cohorted groups.
Further investigation is warranted into whether the find-
ings of this study can be extrapolated to countries with
poorer access to antenatal care, in particular early dating
ultrasound, and hence less accurate GA estimation. More-
over, further studies should compare predictive power for
longer-term outcomes such as neurodevelopment, where
differing SGA proportions would be expected to have
greater effect.
Conclusion
Outcomes of high-risk neonates are commonly reported
either by gestational age or by birth weight. Compared to
gestation-based cohorts, birth weight cohorts are more
prone to selection bias toward small-for-gestational age
infants, who are at high risk of adverse outcomes. How-
ever, this study found cohorts based on VLBW or VLGA
were equally effective when used to generate prediction
models for mortality and morbidity across the three
national neonatal networks of Australia/New Zealand,
Canada and Sweden. Both models had excellent predictive
power when applied to VLGA and VLBW groups, illus-
trating that either model is appropriate for use, pro-
vided GA and BW parameters included in the modeling
have been collected well. Neither model performed well
at the extremes of BW for GA, particularly where it
contained a high proportion of SGA or LGA infants.
The findings of this study may facilitate comparisons
for international benchmarking and subsequent quality
improvement, and provides support for continued
adherence to BW-based cohorting in appropriately
designed population studies.
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